| Janine R Eagle, MD | |
|
One Medical Center Drive, Ophthalmology, Lebanon, NH 03756-0001 | |
| (603) 650-5123 | |
| (603) 676-4090 |
| Full Name | Janine R Eagle |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 30 Years |
| Location | One Medical Center Drive, Lebanon, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265415533 | NPI | - | NPPES |
| 110061703A | Medicaid | MA | |
| 3084523 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 13766 (New Hampshire) | Primary |
| 207W00000X | Ophthalmology | 160082 (Massachusetts) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dartmouth-hitchcock Clinic | 4183537509 | 1139 |
| Mary Hitchcock Memorial Hospital | 4486561164 | 964 |
News Archive
Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).
How do you know when you see something? Researchers at Barrow Neurological Institute in Phoenix have made a breakthrough discovery that puts scientists closer to understanding how visual awareness is generated.
A new study published in the journal Pharmacoepidemiology & Drug Safety reveals that internet sites selling prescription statins directly to consumers are widespread, and that most websites advertising statins for sale to the general public contain very poor levels of information relevant to safe use of the medicine and side effects.
A new report released today by the Collins Center for Public Policy looks beyond the pitched battles over health care reform and instead offers a comprehensive review of the new federal law and its potential impact on Florida.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
› Verified 1 days ago
| Entity Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).
How do you know when you see something? Researchers at Barrow Neurological Institute in Phoenix have made a breakthrough discovery that puts scientists closer to understanding how visual awareness is generated.
A new study published in the journal Pharmacoepidemiology & Drug Safety reveals that internet sites selling prescription statins directly to consumers are widespread, and that most websites advertising statins for sale to the general public contain very poor levels of information relevant to safe use of the medicine and side effects.
A new report released today by the Collins Center for Public Policy looks beyond the pitched battles over health care reform and instead offers a comprehensive review of the new federal law and its potential impact on Florida.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
› Verified 1 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).
How do you know when you see something? Researchers at Barrow Neurological Institute in Phoenix have made a breakthrough discovery that puts scientists closer to understanding how visual awareness is generated.
A new study published in the journal Pharmacoepidemiology & Drug Safety reveals that internet sites selling prescription statins directly to consumers are widespread, and that most websites advertising statins for sale to the general public contain very poor levels of information relevant to safe use of the medicine and side effects.
A new report released today by the Collins Center for Public Policy looks beyond the pitched battles over health care reform and instead offers a comprehensive review of the new federal law and its potential impact on Florida.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
› Verified 1 days ago
| Entity Name | Tallman Eye Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194833467 PECOS PAC ID: 3577501063 Enrollment ID: O20060131000609 |
News Archive
Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).
How do you know when you see something? Researchers at Barrow Neurological Institute in Phoenix have made a breakthrough discovery that puts scientists closer to understanding how visual awareness is generated.
A new study published in the journal Pharmacoepidemiology & Drug Safety reveals that internet sites selling prescription statins directly to consumers are widespread, and that most websites advertising statins for sale to the general public contain very poor levels of information relevant to safe use of the medicine and side effects.
A new report released today by the Collins Center for Public Policy looks beyond the pitched battles over health care reform and instead offers a comprehensive review of the new federal law and its potential impact on Florida.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Janine R Eagle, MD One Medical Center Drive, Ophthalmology, Lebanon, NH 03756-0001 Ph: (603) 650-5123 | Janine R Eagle, MD One Medical Center Drive, Ophthalmology, Lebanon, NH 03756-0001 Ph: (603) 650-5123 |
News Archive
Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).
How do you know when you see something? Researchers at Barrow Neurological Institute in Phoenix have made a breakthrough discovery that puts scientists closer to understanding how visual awareness is generated.
A new study published in the journal Pharmacoepidemiology & Drug Safety reveals that internet sites selling prescription statins directly to consumers are widespread, and that most websites advertising statins for sale to the general public contain very poor levels of information relevant to safe use of the medicine and side effects.
A new report released today by the Collins Center for Public Policy looks beyond the pitched battles over health care reform and instead offers a comprehensive review of the new federal law and its potential impact on Florida.
Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.
› Verified 1 days ago
Dr. William J Rosen, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Dhmc Plastic Surgery, Lebanon, NH 03756 Phone: 603-650-8746 | |
David George Campbell, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-8755 | |
Dr. Robert Michael Schertzer, MD, MED, FRCSC Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Dhmc - Section Of Ophthalmology, Lebanon, NH 03756 Phone: 603-650-8755 | |
Dr. William Gregory Gensheimer, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Drive, Lebanon, NH 03756 Phone: 603-650-5123 | |
Dr. Erin Melissa Salcone, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dartmouth-hitchcock Medical Center, Lebanon, NH 03756 Phone: 603-650-8746 Fax: 603-650-4434 | |
Michael Eric Zegans, M.D Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Section Of Ophthalmology, Lebanon, NH 03756 Phone: 603-650-5123 |